While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
Zelluna: Scientist turns CEO
AppointmentsNorwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.
Antabio SAS advances cystic fibrosis programme
Latest NewsAntabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Creoptix: New woman at the helm
AppointmentsCreoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.
Hydrogel fights wound infection and inflammation
Latest NewsSwedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Is your reality quite different from other people’s reality?
OpinionWhile open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
Is your reality quite different from other people’s reality?
OpinionWhile open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish a completely new model for how to spur innovation. Eliminating intellectual property-related restrictions, open biology promises rapid and local production of biomaterials, diagnostics, or genome-edited crops in countries with no established IP system.
British diagnostics play OBD lands contract with US pharma
Latest NewsThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Iberian biotech newcomer
ProductsThe geographical proximity of Spain’s Northwestern region Galicia to Northern Portugal is a key factor for the birth of the new bioregion CT-Bio. This achievement looks forward to improving business competitiveness and the consolidation of the biotech and life sciences sector internationally.
Determined to grow
OpinionSpanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in the past four years. European Biotechnology spoke with Dámaso Molero, CEO of the Spanish CDMO, about growth perspectives and future strategies.
Truffle’s BioMedTech fund filled with €250m
Latest NewsParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach.